Rentschler, Horizon Ink Cell Line Development Pact

Rentschler Biopharma SE and Horizon Discovery have signed a commercial license agreement under which, Rentschler will use Horizon’s CHOSOURCE platform with its in-house process for cell line development for difficult-to-express proteins. Horizon’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cGMP-compliant cell line will complement Rentschler Biopharma’s existing service offering, providing a royalty-free alternative for the production of highly complex proteins. This will support researchers from early drug development through commercial manufacturing.

Rentschler Biopharma’s integrated platform process, together with Horizon’s cell line, aims to provide tailored solutions to translate complex medical research into biopharmaceuticals. This will elevate the standard of protein expression and allow clients to access a robust and flexible approach for designer protein therapeutics.

Dr. Frank Mathias, CEO of Rentschler Biopharma, said, “At Rentschler Biopharma, we consistently strive to offer our clients optimal and truly integrated solutions across the entire value chain. We achieve this by our own means as well as through strong partnerships. The new collaboration with Horizon, a very renowned company in the area of cell line engineering with an outstanding track record, significantly broadens our fit-for-purpose approach.”

Terry Pizzie, CEO of Horizon Discovery, said, “We are very pleased to be working with such a well-respected organization within the field of biomanufacturing. This agreement brings together two world-class companies in biomanufacturing and further supports our ethos of enabling access to the CHOSOURCE platform in such a way as to empower organizations of all sizes to drive efficiencies in development and production of biotherapeutics.”